INAB logo

IN8BIO INC

INABNASDAQ
🏆 #4827 by market capEarnings Nov 4US Equity
$1.01▲ $0.03 (+3.06%)
Market closed · at close
🔔
Track INAB
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.1%
7d▼ 7.3%
14d▼ 11.4%
30d▼ 21.4%
ytd▼ 56.8%
1y▼ 51.0%
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.01 – $1.01
52-Week Range
$0.87 – $2.73
Volume (shares)
192
Avg Volume (shares)
—
Shares Outstanding
9.9M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-0.5
P/S Ratio
0.0x
EPS (TTM)
$-0.96
Dividend Yield
0.00%
Dilution (1yr)
+304.2%
INAB logo

IN8BIO INC

INAB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$20M▼ −34.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▼ −47.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.8M▲ +304.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24M▲ +$18M YoY
StockOtter · stockotter.space

About IN8BIO INC

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.